Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma through m6A-mediated epitranscriptomic regulation

Background and Aims: Purines are building blocks for the cellular genome, and excessive purine nucleotides are seen in tumors. However, how purine metabolism is dysregulated in tumors, and impacting tumorigenesis remains elusive.Approach and Results: Transcriptomic and metabolomic analyses of purine biosynthesis and purine degradation pathways were performed in the tumor and associated nontumor liver tissues obtained from 62 patients with HCC, one of the most lethal cancers worldwide. We found that most genes in purine synthesis are upregulated, while genes in purine degradation are inhibited in HCC tumors. High purine anabolism is associated with unique somatic mutational signatures linked to patient prognosis. Mechanistically, we discover that increasing purine anabolism promotes epitranscriptomic dysregulation of DNA damage repairing (DDR) machinery through upregulating RNA N6-methyladenosine (m(6)A) modification. High purine anabolic HCC is sensitive to DDR-targeting agents but not to standard HCC treatments, correlating with the clinical outcomes in 5 independent HCC cohorts containing 724 patients. We further showed that high purine anabolism determines the sensitivity to DDR-targeting agents in 5 HCC cell lines in vitro and in vivo.Conclusions: Our results reveal a central role of purine anabolism in regulating DDR, which could be therapeutically exploited in HCC.

Automated summary

In this study, the researchers analyzed the purine metabolism pathways in tumor and non-tumor liver tissues of patients with hepatocellular carcinoma (HCC), one of the most lethal cancers globally. The findings showed that purine synthesis genes are upregulated and purine degradation genes are inhibited in HCC tumors. High purine anabolism is associated with specific somatic mutational signatures and leads to dysregulation of DNA damage repairing machinery. Furthermore, high purine anabolism determines the sensitivity of HCC to DDR-targeting agents and correlates with clinical outcomes.